Attention AACR Annual Meeting 2018 Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Immunotherapy Combinations: The New Frontier in Lung Cancer

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 11 of 11
Chairperson
Alice T Shaw
Massachusetts General Hosp. Cancer Ctr., Boston, MA, United States
from AACR Annual Meeting 2018 on April 16, 2018 10:30 AM-1:05 PM
KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC
Leena Gandhi
NYU Langone Health, New York, NY, United States
from AACR Annual Meeting 2018 on April 16, 2018 10:30 AM-1:05 PM
Discussant
Roy S Herbst
Yale Cancer Ctr., New Haven, CT, United States
from AACR Annual Meeting 2018 on April 16, 2018 10:30 AM-1:05 PM
IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups
Mark A Socinski
Florida Hospital Cancer Institute, Orlando, FL, United States
from AACR Annual Meeting 2018 on April 16, 2018 10:30 AM-1:05 PM
Discussant
Justin F. Gainor
Massachusetts General Hospital, Boston, MA, United States
from AACR Annual Meeting 2018 on April 16, 2018 10:30 AM-1:05 PM
Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227
Matthew D. Hellmann
Memorial Sloan Kettering Cancer Center Hospital, New York, NY, United States
from AACR Annual Meeting 2018 on April 16, 2018 10:30 AM-1:05 PM
Discussant
Naiyer Rizvi
Columbia Univ., New York, NY, United States
from AACR Annual Meeting 2018 on April 16, 2018 10:30 AM-1:05 PM
Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568
Suresh S. Ramalingam
Winship Cancer Institute, Emory University, Atlanta, GA, United States
from AACR Annual Meeting 2018 on April 16, 2018 10:30 AM-1:05 PM
Discussant
David L. Rimm
Yale Univ. School of Medicine, New Haven, CT, United States
from AACR Annual Meeting 2018 on April 16, 2018 10:30 AM-1:05 PM
Neoadjuvant PD-1 blockade in resectable lung cancer
Drew M Pardoll
Johns Hopkins Sidney Kimmel Comp. Cancer Ctr., Baltimore, MD, United States
from AACR Annual Meeting 2018 on April 16, 2018 10:30 AM-1:05 PM
Discussant
John Heymach
UT MD Anderson Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2018 on April 16, 2018 10:30 AM-1:05 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 11 of 11